Stuart Lutzker, MD, PhD
Scientific Advisory Board Member
Dr. Stuart Lutzker is an industry veteran with decades of oncology drug development and leadership experience. Most recently, Dr. Lutzker was Vice President of Oncology Early Clinical Development at Genentech from 2009-2021 where he led the early development of multiple now approved oncology drugs including Kadcyla®, Polivy®, Venclexta®, Cotellic® and Tecentriq®. Prior to Genentech, Dr. Lutzker was a medical oncologist and cancer researcher at the NCI-Designated Cancer Institute of New Jersey, where he divided his time between patient care and laboratory-based cancer research. Dr. Lutzker received his M.D./Ph.D. in Biochemistry from Columbia University College of Physicians and Surgeons. Following his residency and fellowship in Internal Medicine and Medical Oncology at Yale-New Haven Hospital, Dr. Lutzker completed post-doctoral research training in the Department of Molecular Biology at Princeton University. Dr. Lutzker has also served as faculty for the ASCO/AACR Methods in Clinical Cancer Research Workshop in Vail, CO.
Statement: "I am incredibly excited to join the Aarvik SAB to provide early drug development advice as Aarvik advances its unique ADC platform towards the clinic. The scientific experience of the co-founders in antibody engineering, linker-drug synthesis and ADC design is world class and together Aarvik will build on the success of 1st and 2nd generation ADC platforms that are benefitting many patients today across both liquid and solid tumors."